Fennec Pharmaceuticals Completes Rolling Submission of NDA to U.S. FDA for Pedmark; Submits MAA to European Medicines Agency

Fennec Pharmaceuticals Completes Rolling Submission of NDA to U.S. FDA for Pedmark; Submits MAA to European Medicines Agency

Fennec Pharmaceuticals announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Pedmark (a unique formulation of sodium thiosulfate) for intravenous use and submitted a Marketing Authorization...
Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for Phase 2 Trial of LYR-210 for Chronic Rhinosinusitis

Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for Phase 2 Trial of LYR-210 for Chronic Rhinosinusitis

Lyra Therapeutics announced the U.S. FDA has cleared the company’s Investigational New Drug (IND) application for LYR-210 for the treatment of chronic rhinosinusitis (CRS). Lyra plans to incorporate U.S. clinical sites into LANTERN, its ongoing global Phase 2 clinical...
Charlotte NC Provider CEENTA Seeks Clinical Research Coordinator for Clinical Trials

Charlotte NC Provider CEENTA Seeks Clinical Research Coordinator for Clinical Trials

Charlotte Eye Ear Nose & Throat Associates, P.A. (CEENTA) has been a Charlotte, North Carolina region premier eye, ear, nose and throat care provider for adults and pediatric patients for nearly 100 years. With the largest multi-specialty practice on the East...

Pin It on Pinterest